Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity

Evidence accumulates that the transcription factor nuclear factor E2-related factor 2 (Nrf2) has an essential role in cancer development and chemoresistance, thus pointing to its potential as an anticancer target and undermining its suitability in chemoprevention. Through the induction of cytoprotective and proteasomal genes, Nrf2 confers apoptosis protection in tumor cells, and inhibiting Nrf2 would therefore be an efficient strategy in anticancer therapy. In the present study, pancreatic carcinoma cell lines (Panc1, Colo357 and MiaPaca2) and H6c7 pancreatic duct cells were analyzed for the Nrf2-inhibitory effect of the coffee alkaloid trigonelline (trig), as well as for its impact on Nrf2-dependent proteasome activity and resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and anticancer drug-induced apoptosis. Chemoresistant Panc1 and Colo357 cells exhibit high constitutive Nrf2 activity, whereas chemosensitive MiaPaca2 and H6c7 cells display little basal but strong tert-butylhydroquinone (tBHQ)-inducible Nrf2 activity and drug resistance. Trig efficiently decreased basal and tBHQ-induced Nrf2 activity in all cell lines, an effect relying on a reduced nuclear accumulation of the Nrf2 protein. Along with Nrf2 inhibition, trig blocked the Nrf2-dependent expression of proteasomal genes (for example, s5a/psmd4 and α5/psma5) and reduced proteasome activity in all cell lines tested. These blocking effects were absent after treatment with Nrf2 siRNA, a condition in which proteasomal gene expression and proteasome activity were already decreased, whereas siRNA against the related transcription factor Nrf1 did not affect proteasome activity and the inhibitory effect of trig. Depending on both Nrf2 and proteasomal gene expression, the sensitivity of all cell lines to anticancer drugs and TRAIL-induced apoptosis was enhanced by trig. Moreover, greater antitumor responses toward anticancer drug treatment were observed in tumor-bearing mice when receiving trig. In conclusion, representing an efficient Nrf2 inhibitor capable of blocking Nrf2-dependent proteasome activity and thereby apoptosis protection in pancreatic cancer cells, trig might be beneficial in improving anticancer therapy.

[1]  M. Moore,et al.  Advanced pancreatic carcinoma: current treatment and future challenges , 2010, Nature Reviews Clinical Oncology.

[2]  D. Lubahn,et al.  ERRβ: A potent inhibitor of Nrf2 transcriptional activity , 2007, Molecular and Cellular Endocrinology.

[3]  J. Hampe,et al.  Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2) , 2009, Oncogene.

[4]  Choongseob Oh,et al.  Functional differences between two major ubiquitin receptors in the proteasome; S5a and hRpn13. , 2010, Biochemical and biophysical research communications.

[5]  I. Rahman,et al.  Nrf2-ARE stress response mechanism: A control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases , 2010, Free radical research.

[6]  M. Kwak,et al.  Antioxidants Enhance Mammalian Proteasome Expression through the Keap1-Nrf2 Signaling Pathway , 2003, Molecular and Cellular Biology.

[7]  William E Grizzle,et al.  The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma , 2000, Oncogene.

[8]  M. Kwak,et al.  NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. , 2011, Cancer research.

[9]  P. Carmeliet,et al.  Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling , 2011, Cancer cell.

[10]  Stephen G Swisher,et al.  Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features , 2010, Clinical Cancer Research.

[11]  Michael H A Roehrl,et al.  Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. , 2008, Journal of proteome research.

[12]  K. Kwon,et al.  Nuclear Factor (Erythroid-Derived 2)-Like 2 Regulates Drug Resistance in Pancreatic Cancer Cells , 2010, Pancreas.

[13]  C. B. Pickett,et al.  The Nrf2-Antioxidant Response Element Signaling Pathway and Its Activation by Oxidative Stress* , 2009, Journal of Biological Chemistry.

[14]  S. Werner,et al.  Hepatitis B Virus Induces Expression of Antioxidant Response Element-regulated Genes by Activation of Nrf2* , 2010, The Journal of Biological Chemistry.

[15]  Youming Xie.  Feedback regulation of proteasome gene expression and its implications in cancer therapy , 2010, Cancer and Metastasis Reviews.

[16]  M. McMahon,et al.  NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. , 2009, Trends in biochemical sciences.

[17]  P. Nioi,et al.  A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. , 2007, Biochemical and biophysical research communications.

[18]  Ying Yan,et al.  Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells. , 2011, The Journal of clinical endocrinology and metabolism.

[19]  T. Kensler,et al.  Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. , 2008, Mutation research.

[20]  Y. Hu,et al.  Mutation of the Nrf2 gene in non-small cell lung cancer , 2012, Molecular Biology Reports.

[21]  S. Cannistra,et al.  Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. , 2011, Cancer research.

[22]  N. Chondrogianni,et al.  Nuclear Erythroid Factor 2-mediated Proteasome Activation Delays Senescence in Human Fibroblasts* , 2010, The Journal of Biological Chemistry.

[23]  C. B. Pickett,et al.  Nrf2 Controls Constitutive and Inducible Expression of ARE-driven Genes through a Dynamic Pathway Involving Nucleocytoplasmic Shuttling by Keap1* , 2005, Journal of Biological Chemistry.

[24]  D. Lubahn,et al.  ERRbeta: a potent inhibitor of Nrf2 transcriptional activity. , 2007, Molecular and cellular endocrinology.

[25]  A. Jaiswal,et al.  Low and high dose UVB regulation of transcription factor NF-E2-related factor 2. , 2006, Cancer research.

[26]  Fiona Campbell,et al.  Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy , 2011, Molecular Cancer.

[27]  G. Pahlke,et al.  Coffee constituents as modulators of Nrf2 nuclear translocation and ARE (EpRE)-dependent gene expression. , 2011, The Journal of nutritional biochemistry.

[28]  Weimin Chen,et al.  Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. , 2008, Carcinogenesis.

[29]  C. Wolf,et al.  Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha , 2007, Proceedings of the National Academy of Sciences.

[30]  Li Chen,et al.  Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. , 2005, Cancer research.

[31]  Ken Itoh,et al.  Modulation of Gene Expression by Cancer Chemopreventive Dithiolethiones through the Keap1-Nrf2 Pathway , 2003, The Journal of Biological Chemistry.

[32]  R. Heine,et al.  Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on incretin hormones , 2011, Nutrition & metabolism.

[33]  E. Krüger,et al.  Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. , 2010, Molecular cell.

[34]  R. Deshaies,et al.  Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. , 2010, Molecular cell.

[35]  D. Saur,et al.  HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA , 2009, Gut.

[36]  Y. Surh,et al.  A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. , 2010, Mutation research.

[37]  P. Altevogt,et al.  Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-β1 (TGF-β)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells. , 2010, International journal of oncology.

[38]  Kwon-Sik Park,et al.  Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. , 2011, Cancer cell.

[39]  Donna D. Zhang.  The Nrf2-Keap1-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer. , 2010, Antioxidants & redox signaling.

[40]  B. Aggarwal,et al.  Oxidative stress, inflammation, and cancer: how are they linked? , 2010, Free radical biology & medicine.

[41]  S. Niture,et al.  Prothymosin-α Mediates Nuclear Import of the INrf2/Cul3·Rbx1 Complex to Degrade Nuclear Nrf2* , 2009, Journal of Biological Chemistry.

[42]  A. Guillouzo,et al.  Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells. , 2009, European journal of cancer.

[43]  N. Grishin,et al.  Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. , 2011, Cancer cell.

[44]  N. Chen,et al.  High levels of Nrf2 determine chemoresistance in type II endometrial cancer. , 2010, Cancer research.

[45]  Rui Wang,et al.  Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. , 2008, Biochemical and biophysical research communications.

[46]  Scott E. Kern,et al.  Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis , 2011, Nature.

[47]  M. R. Kim,et al.  Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. , 2008, Free radical biology & medicine.

[48]  Ken Itoh,et al.  Enhanced Expression of the Transcription Factor Nrf2 by Cancer Chemopreventive Agents: Role of Antioxidant Response Element-Like Sequences in the nrf2 Promoter , 2002, Molecular and Cellular Biology.

[49]  Qun Zhou,et al.  miR-200a Regulates Nrf2 Activation by Targeting Keap1 mRNA in Breast Cancer Cells* , 2011, The Journal of Biological Chemistry.

[50]  C. Geismann,et al.  Inflammatory Macrophages Induce Nrf2 Transcription Factor-dependent Proteasome Activity in Colonic NCM460 Cells and Thereby Confer Anti-apoptotic Protection* , 2011, The Journal of Biological Chemistry.

[51]  P. Wong,et al.  Dual roles of Nrf2 in cancer. , 2008, Pharmacological research.

[52]  Xiao-tong Hu,et al.  Depletion of the proteasome subunit PSMA7 inhibits colorectal cancer cell tumorigenicity and migration. , 2009, Oncology reports.

[53]  R. Heine,et al.  Acute Effects of Decaffeinated Coffee and the Major Coffee Components Chlorogenic Acid and Trigonelline on Glucose Tolerance , 2009, Diabetes Care.

[54]  S. Biswal,et al.  Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. , 2010, Antioxidants & redox signaling.

[55]  H. Kalthoff,et al.  Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin , 2001, Oncogene.

[56]  N. Yoo,et al.  Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin , 2010, The Journal of pathology.

[57]  M. Kwak,et al.  Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. , 2009, Free radical biology & medicine.

[58]  M. Kwak,et al.  Induction of 26S proteasome subunit PSMB5 by the bifunctional inducer 3-methylcholanthrene through the Nrf2-ARE, but not the AhR/Arnt-XRE, pathway. , 2006, Biochemical and biophysical research communications.